PT - JOURNAL ARTICLE AU - Lingas, Guillaume AU - Néant, Nadège AU - Gaymard, Alexandre AU - Belhadi, Drifa AU - Peytavin, Gilles AU - Hites, Maya AU - Staub, Thérèse AU - Greil, Richard AU - Paiva, Jose-Artur AU - Poissy, Julien AU - Peiffer-Smadja, Nathan AU - Costagliola, Dominique AU - Yazdanpanah, Yazdan AU - Wallet, Florent AU - Gagneux-Brunon, Amandine AU - Mentré, France AU - Ader, Florence AU - Burdet, Charles AU - Guedj, Jérémie AU - Bouscambert-Duchamp, Maude AU - , TI - Modeling remdesivir antiviral efficacy in COVID-19 hospitalized patients of the randomized, controlled, open-label DisCoVeRy trial AID - 10.1101/2021.10.19.21265209 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.19.21265209 4099 - http://medrxiv.org/content/early/2021/10/20/2021.10.19.21265209.short 4100 - http://medrxiv.org/content/early/2021/10/20/2021.10.19.21265209.full AB - Despite several clinical studies, the antiviral efficacy of remdesivir in COVID-19 hospitalized patients remains controversial. We analyzed nasopharyngeal normalized viral loads collected in the 29 days following randomization from 665 hospitalized patients included in the DisCoVeRy trial, allocated to either standard of care (SoC, N=329) or SoC + remdesivir for 10 days (N=336). We used a mathematical model to reconstruct viral kinetic profiles and estimate the antiviral efficacy of remdesivir in reducing viral production. To identify factors associated with viral kinetics, additional analyses were conducted stratified either on time of treatment initiation (≤ or > 7 days since symptom onset) or viral load at randomization (< or ≥ 3.5 log10 copies/104 cells). In our model, remdesivir reduced viral production by 2-fold on average (95%CI: 1.5-3.2). Using the estimated parameter of the model, simulations predict that remdesivir reduces time to viral clearance by 0.7 day compared to SoC, with large inter-individual variabilities (Inter-Quartile Range, IQR: 0.0-1.3 days). Exploratory analyses suggest that remdesivir had a larger impact in patients with a high viral load at randomization, reducing viral production by 5-fold on average (95%CI: 2.8-25), leading to a predicted median reduction in the time to viral clearance of 2.4 days (IQR: 0.9-4.5 days).In summary, our model shows that remdesivir reduces viral production from infected cells by a factor 2, leading to a median reduction of 0.7 days in the time to viral clearance compared to SoC. The efficacy was larger in patients with high level of viral load at treatment initiation.One sentence summary Remdesivir reduces the time to SARS-CoV-2 clearance by 1 day in hospitalized patients, and up to 3 days in those with high viral load at admission.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04315948Funding StatementEuropean Union Commission, French Ministry of Health, DIM One Health Ile-de- France, REACTing, Fonds Erasme-COVID-ULB; Belgian Health Care Knowledge Centre (KCE)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the Ethics Committee (CPP Ile-de-France-III, approval #20.03.06.51744)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors